ADAM19 and neoplasm: Our investigation unveils two novel biomarkers: nbTMB (non-B-informed TMB) and mlTNB (mutation-localised tumour non-B DNA burden), aiming to quantify the multi-dimensions of genomic instability using both tumour mutations and non-B DNA at a sample level.